Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (3279)	6/11/1999 7:58:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 10280

Saw the following quote from one of yesterday's PRs that mentions Sepracor: ''Amgen is successful because Gordon Binder is a CFO trained under Harry Gray,'' Swarz said. ''Centocor's David Holveck, Genzyme's Henri Termeer, Biogen's Jim Vincent, and Immunex's Ed Fritzky exemplify CEOs who know how to run businesses and have the right foundational experience.'' That guy Swarz really knows how to go out on a limb. I mean, the headline of this PR was something like "Swarz skewers Biotech Management" and it turns out that he just takes a list of successful companies, calls their management great, and then says the rest need better management. Circular and weak. This is a prime example of why you get better opinions and information from SI than from "professionals".